MAP1A在膀胱癌组织中的表达及其与临床病理特征的关系

doi:10.11904/j.issn.1002-3070.2019.06.009

摘要/Abstract

摘要： 目的探讨微管相关蛋白1A(Microtubule associated protein 1A,MAP1A)在膀胱癌组织中的表达及其与临床病理特征的相关性。方法收集2011年1月—2016年1月西安交通大学第一附属医院膀胱癌及癌旁组织137例,qPCR及免疫组化分析MAP1A在膀胱癌及癌旁组织中的表达情况;并研究其表达与膀胱癌临床病理参数及预后的关系。结果 qPCR结果表明,MAP1A在20例膀胱癌组织中表达水平较配对的癌旁组织明显降低,差异有统计学意义(t=5.022,P＜0.001)。免疫组化结果同样表明,MAP1A在膀胱癌组织和癌旁组织中的阳性表达率分别为46.71%和79.56%,差异具有统计学意义(χ²=23.52,P＜0.0001)。MAP1A表达与患者的临床T分期、淋巴结转移及TNM分期密切相关(P＜0.05)。Kaplan-Meier生存分析发现,MAP1A低表达患者总生存期(Overall survival,OS)和无病生存期(Disease-free survival,DFS)均明显低于MAP1A高表达患者(P＜0.0001)。Cox多因素回归分析表明TNM分期(HR=1.46,P=0.038)和MPA1A表达(HR=1.213,P=0.030)是影响膀胱癌患者不良预后的独立危险因素。结论 MAP1A在膀胱癌组织中显著低表达,与临床TNM分期密切相关,MAP1A低表达可能提示膀胱癌患者不良预后。

关键词: 膀胱癌, 微管相关蛋白1A, 临床病理特征, 预后

Abstract: Objective The objective of this study was to investigate the expression of microtubule associated protein 1A(MAP1A)in bladder cancer and its correlation with clinicopathological features.Methods One hundred and thirty seven cases of bladder cancer and adjacent tissues were collected.qRT-PCR and immunohistochemistry were used to analyze the expression of MAP1A in bladder cancer and adjacent tissues.The relationship between the expression of MAP1A and clinicopathological parameters & prognosis of bladder cancer patients was studied.Results The results of qRT-PCR showed that the expression level of MAP1A in 20 cases of bladder cancer was significantly lower than that of the matched adjacent tissues(t=5.022,P＜0.001).The results of immunohistochemistry also showed that the positive expression rates of MAP1A in bladder cancer and adjacent tissues were 46.71%(46/37)and 79.56%(109/137),respectively,and the difference was statistically significant(χ²=23.52,P＜0.0001).The expression of MAP1A was closely related to clinical T stage,lymph node metastasis and TNM stage(χ²=9.982,P=0.0016;χ²=8.064,P=0.0045;χ²=7.199,P＜0.0073).Kaplan-Meier survival analysis showed that the overall survival(OS)and disease-free survival(DFS)of patients with low expression of MAP1A were significantly shorter than those with high expression of MAP1A(χ²=26.74,P＜0.0001;χ²=18.73,P＜0.0001).Cox multivariate regression analysis showed that TNM stage(HR=1.46,P=0.038)and MAP1A expression(HR=1.213,P=0.030)were independent risk factors for adverse prognosis of bladder cancer patients.Conclusion MAP1A is significantly down-regulated in bladder cancer tissues and is closely related to clinical TNM staging.The low expression of MAP1A may indicate the poor prognosis of bladder cancer patients.

Key words: Bladder cancer, Microtubule associated protein 1A, Clinicopathological features, Prognosis

中图分类号:

R694

范晋海, 蒋玉梅, 张静, 白晓静. MAP1A在膀胱癌组织中的表达及其与临床病理特征的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 525-530.

FAN Jinhai, JIANG Yumei, ZHANG Jing, BAI Xiaojing. Expression of MAP1A in bladder cancer and its correlation with clinicopathological features[J]. Journal of Practical Oncology, 2019, 33(6): 525-530.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.06.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I6/525

参考文献

1 DeSantis CE,Miller KD,Dale W,et al.Cancer statistics for adults aged 85 years and older,2019[J].CA Cancer J Clin,2019.
2 Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34.
3 Lotan Y,Black PC,Caba L,et al.Optimal trial design for studying urinary markers in bladder cancer:a collaborative review[J].Eur Urol Oncol,2018,1(3):223-230.
4 Humayun-Zakaria N,Arnold R,Goel A,et al.Tropomyosins:potential biomarkers for urothelial bladder cancer[J].Int J Mol Sci,2019,20(5):1102.
5 Miyamoto DT,Mouw KW,Feng FY,et al.Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer[J].Lancet Oncol,2018,19(12):683-695.
6 冯思坛.微管相关蛋白与肿瘤关系的研究进展[J].医学研究生学报,2013,26(8):878-881.
7 李建华,王润泽,李伟民.微管相关蛋白与自噬的研究进展[J].吉林医药学院学报,2018,39(4):285-290.
8 Nakayama A,Odajima T,Murakami H,et al.Characterization of two promoters that regulate alternative transcripts in the microtubule-associated protein(MAP)1A gene[J].Biochim Biophys Acta,2001,1518(3):260-266.
9 Grossman GH,Beight CD,Ebke LA,et al.Interaction of tubby-like protein-1(Tulp1)and microtubule-associated protein(MAP)1A and MAP1B in the mouse retina[J].Adv Exp Med Biol,2014,801:511-518.
10 Mohan R,John A.Microtubule-associated proteins as direct crosslinkers of actin filaments and microtubules[J].IUBMB Life,2015,67(6):395-403.
11 Perez Y,Bar-Yaacov R,Kadir R,et al.Mutations in the microtubule-associated protein MAP11(C7orf43)cause microcephaly in humans and zebrafish[J].Brain,2019,142(3):574-585.
12 Meyer MA.Highly expressed genes in human high grade gliomas:immunohistochemical analysis of data from the human protein atlas[J].Neurol Int,2014,6(2):5348.
13 Song K,Hu W,Yue F,et al.Transforming growth factor TGFβ increases levels of microtubule-associated protein MAP1S and autophagy flux in pancreatic ductal adenocarcinomas[J].PLoS One,2015,10(11):e0143150.
14 Jiang X,Zhong W,Huang H,et al.Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients[J].Mol Carcinog,2015,54(10):1194-204.
15 Knutson TP,Daniel AR,Fan D,et al.Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression[J].Breast Cancer Res,2012,14(3):95.

[1]	刘耿淳, 申良方. 血清长链非编码RNA MALAT1和AFAP1-AS1与鼻咽癌临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 513-518.
[2]	刘四卫, 崔玥, 孙元元, 胡晶, 张文睿, 曹孟儒. FOXD3在肺癌细胞中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 390-396.
[3]	夏天一, 张博淼, 姚克非, 崔滨滨. PTPN9表达水平与结直肠癌的临床关系研究[J]. 实用肿瘤学杂志, 2019, 33(5): 415-419.
[4]	徐亭, 严斐斐, 张纯慧, 张艳桥. 胃癌骨转移患者临床病理与预后分析[J]. 实用肿瘤学杂志, 2019, 33(5): 436-441.
[5]	李思维 , 庞达. 长链非编码RNA(lncRNA)在癌症中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 471-475.
[6]	曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.
[7]	刘金涛, 高玲, 周会会. MAGEA4和EB1蛋白在肺癌组织中的表达及其与临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(4): 334-339.
[8]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[9]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[10]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[11]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[12]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[13]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[14]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[15]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.